Agenus INC 8-K filings

Agenus Inc. announced second quarter 2026 financial results and provided an update on its Phase 3 ROBBIN trial for botensilimab (BOT) + balstilimab (BAL) in neoadjuvant MSS colon cancer, supported by an $85 million private placement.

Agenus Inc. announced a private placement raising over $85 million, with potential for up to $340 million, to fund its Phase 3 ROBBIN trial for neoadjuvant BOT+BAL in MSS colon cancer.

Agenus Inc. has amended terms on existing notes and extended the expiration dates of several series of warrants, while also issuing new warrants.

Agenus Inc. announced first quarter 2026 financial results, highlighting progress in its BOT+BAL program, including Phase 3 trial enrollment and a strategic collaboration with Zydus.

Agenus Inc. and its executives achieved a complete dismissal of a putative securities class action lawsuit in federal court.

Agenus Inc. announced its BOT+BAL immunotherapy program advanced to global Phase 3, expanded early access programs, and recognized initial revenues, alongside its Q4 and full year 2025 financial results.

Agenus Inc. announced the closing of its strategic collaboration with Zydus Lifesciences, securing $141 million in capital and manufacturing capacity to advance its BOT+BAL immunotherapy program.

Agenus Inc. announced the appointment of Dr. Garo Armen as interim Chief Financial Officer and Principal Financial Officer, and Austin Charette as Principal Accounting Officer, effective January 8, 2026.

Agenus Inc. has amended its agreement with Ligand Pharmaceuticals, securing a release of liens on its assets in exchange for a reduced warrant exercise price.

Agenus Inc. reported strong Q3 2025 results, highlighted by French government-funded access for BOT/BAL, positive long-term survival data, and the initiation of a global Phase 3 trial.

Agenus Inc. entered into a Promissory Note Agreement for up to $10 million with Zydus Pharmaceuticals, collateralized by MiNK Therapeutics shares, to fund Q4 2025 operations.

AGENUS Inc. announced a delay in the closing of its strategic agreements with Zydus Pharmaceuticals (USA) Inc. to Q4 2025, following a request for a full notice application from CFIUS.

Agenus Inc. announced improved second quarter 2025 financial results and significant clinical and regulatory progress for its lead immunotherapy combination, botensilimab and balstilimab.

Agenus Inc. announced the results of its Annual Meeting of Stockholders, where key equity plan amendments were approved, but a one-time option exchange and executive compensation received shareholder rejection.

Agenus Inc. has entered into a comprehensive strategic collaboration with Zydus Lifesciences, including the sale of its manufacturing assets for up to $125 million, a $16 million equity investment, and an exclusive licensing agreement for its BOT/BAL cancer immunotherapy in India and Sri Lanka.

Agenus Inc. announces Q1 2025 financial results and key business updates, highlighting breakthrough response rates in MSS cancers with its BOT/BAL program and a near-term capital transaction to bolster liquidity.

Agenus reports Q4 and year-end 2024 results, highlighting strategic operational improvements and significant cost reductions to enhance the sustainability of its promising BOT/BAL program.

Agenus Inc. has amended its agreements with existing noteholders to extend the maturity date of senior subordinated promissory notes, increase the interest rate, and issue new warrants to purchase common stock.

Agenus Inc. will regain full control of its LAG-3 and TIM-3 immuno-oncology programs following Incyte's decision to terminate their licensing agreement, effective February 4, 2026.

Agenus Inc. is streamlining operations, reducing costs by 60%, and focusing on its lead botensilimab/balstilimab program to achieve a $100 million cash burn target for 2025.

Agenus has secured a $22 million mortgage and is implementing a strategic operational realignment plan to focus on its botensilimab/balstilimab program and reduce costs.

Agenus announced its Q3 2024 financial results, highlighting clinical progress with its BOT/BAL cancer treatment and strategic financial initiatives to strengthen its position.

Agenus Inc. has amended its previous 8-K filing to announce Thomas L. Harrison's appointment to the Audit and Finance Committee as chair, and the Corporate Governance and Nominating Committee, effective November 5, 2024.

Agenus Inc. announces the resignation of director Ulf Wiinberg, effective November 5, 2024, who will transition to a senior advisor role.

Agenus reported its second quarter 2024 financial results, appointed a new board member, and announced an at-the-market offering of common stock.

Bristol Myers Squibb has terminated its license agreement for Agenus's AGEN1777, returning full rights to Agenus effective January 26, 2025.

Agenus Inc. has appointed Dr. Jennifer Buell to its Board of Directors, effective immediately, to leverage her extensive biopharmaceutical experience and strategic vision.

Agenus Inc. held its annual meeting on June 11, 2024, where stockholders elected a director, approved amendments to equity and compensation plans, and ratified the appointment of KPMG LLP as the company's auditor.

Agenus Inc. finalized the sale of a portion of its milestone and royalty rights to Ligand Pharmaceuticals for $75 million, marking a significant financial transaction.

Agenus announced a $100 million royalty financing agreement with Ligand and reported positive clinical results for its botensilimab/balstilimab combination therapy in colorectal cancer.